Health Canada Approves Concentrated Version of Alpha1-Proteinase Inhibitor
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Health Canada Approves Concentrated Version of Alpha1-Proteinase Inhibitor

NEW YORK -- February 17, 2010 -- Health Canada has approved a more purified and concentrated version of Alpha1-Proteinase Inhibitor (Human; Prolastin-C) for the treatment of panacinar emphysema in patients with alpha1-antitrypsin (AAT) deficiency.

The concentrated version, which will replace the original version, delivers twice the active protein per millilitre, cutting infusion volume and time in half when given at the recommended rate of 0.08 mL/kg/min.

Clinical studies have shown that Prolastin-C and Prolastin are equally effective at raising AAT levels in the blood. In clinical trials, the most common drug-related adverse reactions observed at a rate of >= 1% in patients receiving Prolastin-C were chills, malaise, headache, rash, hot flush, and pruritus.

The manufacturer, Talecris Biotherapeutics, will provide information about the transition from Prolastin to Prolastin-C through the product’s distribution program and through pharmacies that assist physicians and their patients who currently receive Prolastin therapy.

SOURCE: Talecris Biotherapeutics

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities